- Staat
- MN
- Alter
- 8,0
- Geschlecht
- F
- Eingang
- 16.02.2023
- Impfdatum
- 16.02.2023
- Beginn
- 16.02.2023
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / LL
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Anxiety
Syncope
Symptomtext
After patient had received all of the vaccines she had fainted while being held by the social worker. She woke up within a minute of fainting and then was given apple juice and crackers to help get her feeling better. We also gave her an ice pack for the back of her neck. Patient was also very anxious to receive vaccines before we had even started.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Syncope
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- CO
- Alter
- 12,0
- Geschlecht
- F
- Eingang
- 14.02.2023
- Impfdatum
- 14.02.2023
- Beginn
- 14.02.2023
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / RA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Dizziness
Increased bronchial secretion
Loss of consciousness
Nausea
Symptomtext
1325 Client received vaccinations 1330 Client lost consciousness x2, experienced dizziness, nausea, gurgling, possible apnea, and arm flexion Placed client on side 1338 Called EMS 1348 EMS arrived and evaluated client, clients symptoms resolved and client declined transport
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Loss of consciousness
- Hospital-Tage
- -
- Labordaten
- None
- Aktuelle Erkrankungen
- None
- Vorgeschichte
- None
- Andere Medikamente
- No known medications
- Allergien
- NKA
- Vorherige Impfungen
- -
- Staat
- AZ
- Alter
- 15,0
- Geschlecht
- F
- Eingang
- 11.01.2023
- Impfdatum
- 10.01.2023
- Beginn
- 10.01.2023
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Fall
Head injury
Syncope
Symptomtext
Client fainted and fell off the chair in waiting area after receiving vaccines. Client's legs raised while client was lying down. BP 130/80 HR 70. Ice compress placed on head. Provided juice and crackers, which client ate and drank. Client stated she bumped her head when she fell. Client walked to back area after stating she was feeling better. Vitals retaken. Supine: 134/79 HR 69 Sitting: 129/84 HR 62 Advised client and parents of signs of concussion and what to do if signs/symptoms appear . Client voided before being released at 30 minute mark per NP's advisement.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Syncope
- Hospital-Tage
- -
- Labordaten
- NA
- Aktuelle Erkrankungen
- None
- Vorgeschichte
- None
- Andere Medikamente
- None
- Allergien
- None
- Vorherige Impfungen
- -
- Staat
- MI
- Alter
- 16,0
- Geschlecht
- F
- Eingang
- 08.11.2022
- Impfdatum
- 07.11.2022
- Beginn
- 07.11.2022
- Tage bis Beginn
- 0,0
- Dosis
- 2
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Immediate post-injection reaction
Syncope
Symptomtext
Syncope immediately after vaccination
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Syncope
- Hospital-Tage
- -
- Labordaten
- None
- Aktuelle Erkrankungen
- none
- Vorgeschichte
- none
- Andere Medikamente
- None
- Allergien
- None
- Vorherige Impfungen
- -
- Staat
- -
- Alter
- 11,0
- Geschlecht
- F
- Eingang
- 20.10.2022
- Impfdatum
- 20.10.2022
- Beginn
- 20.10.2022
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Fall
Syncope
Symptomtext
vaccines Tdap and Meningococcal were given in the left arm, and then influenza and HPV in the right arm. HPV was given last. Patient slumped forward less than one minute after receiving the HPV and had fainted. No injury came of this. Nurses safely repositioned to laying down on her back with legs elevated and she came to in two minutes or less. Vitals were obtained and appeared stable. MD was notified of incident and came to assess patient and deemed it safe for her to continue home after a few minutes.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Syncope
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- ND
- Alter
- 16,0
- Geschlecht
- M
- Eingang
- 22.09.2022
- Impfdatum
- 22.09.2022
- Beginn
- 22.09.2022
- Tage bis Beginn
- 0,0
- Dosis
- 2
- Route/Site
- IM / RA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Cataplexy
Cold sweat
Musculoskeletal stiffness
Pallor
Seizure like phenomena
Symptomtext
Mother signed form and sent back via email to nurse with permission to give 2nd Menactra and 1st Men B. Pt came in the room acting normal not anxious. Nurse gave MCV4 to pts R deltoid with no issues. Nurse was giving Men B and while she was giving it pt went pale and his head went down to his chest and body went limp. After about 5 seconds pt's arms and hands came in towards his body and became stiff. after another 5 seconds pt's arms went out towards his sides and remained stiff and body was tight and his head went back. After another 5 seconds pt's body came out of the stiffness and into a normal state. Pt started to respond to nurses. He remained pale and clammy. It was about a total of 20 seconds pt was in the state of seizure like activity. Nurse called Mother and stated to her what happened and that at this time pt was back in his normal state but just pale. Nurse stated to mother that nurses are with pt but nurse would like pt to be seen by a doctor. Mother said she will be on her way. The last time pt got vaccines he was pale, dizzy, and lightheaded. Nurse got ice and water for pt. Pt remained pale and clammy for about 5 minutes. Pt regained color and stated he felt "normal" or as he did before the shots just a "little clammy" still. Pt drank about two cups of water and remained sitting in chair until parents came. Nurses explained to parents what happened and gave list of what was given to pt and in what arm. Nurse explained that this will be reported to CDC and that she can refuse the next vaccination. Parents took pt from the room and were taking him straight to the ER to be seen. Nurse stated to call the office if they had any further discussion.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Seizure like phenomena
- Hospital-Tage
- -
- Labordaten
- Pt was taken to ER right after parents got to the school.
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- After his last vaccinations back in 2018 pt became pale, dizzy, and lightheaded but felt better after sips of water and a wet towel around his neck.
- Andere Medikamente
- -
- Allergien
- Fish
- Vorherige Impfungen
- Pt got dizzy, lightheaded, and pale after receiving Menactra on 8/16/2018.
- Staat
- ID
- Alter
- 17,0
- Geschlecht
- F
- Eingang
- 08.12.2022
- Impfdatum
- 07.12.2022
- Beginn
- 07.12.2022
- Tage bis Beginn
- 0,0
- Dosis
- 2
- Route/Site
- IM / RA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Disorientation
Dizziness
Muscular weakness
Pallor
Speech disorder
Tremor
Symptomtext
INITIAL VACCINE ADMINISTRATION, PT WAS DOING OK. PT REMAINED SITTING, NO CONCERNS NOTED. SMALL CONVERSATION WITH PT WAS MADE, PT WAS SMILING. EDUCATED PT ON COMFORT MEASURES AFTER INJECTION, POSSIBLE PAIN FROM INJECTION, ENCOURAGED COMFORT MEASURES TO PERFORM AT HOME. PT AND MOTHER AGREED. PT REMAINED SITTING FOR APROXIMATELY 7-8 MORE MIN AND EXPRESS SHE WAS FEELING FINE. PT AND MOTHER WAS PROCEEDING TO CHECK OUT. PT WAS AGAIN ASKED HOW SHE WAS DOING, PT STATED SHE WAS FINE. HER AND HER MOTHER CONTINUED TO WALK AWAY. I DECIDED TO FOLLOW PT TO CHECK OUT DESK AND THAT IS WHEN I SEEN HER TURN TO HER MOTHER AND STATE SHE WAS FEELING DIZZY, PT THEN GOT SHAKEY, HER LEGS STARTED TO BUCKLE UNDER HER, I IMMEDIATELY GRABBED HER ALONG WITH HER MOTHER AND DIRECTED HER TO A CHAIR NEAR BY. MOTHER WAS INSTRUCTED TO STAY NEXT TO HER SIDE, I PROCEDED TO GET THE PROVIDER AND ADVISE HER WHAT WAS HAPPENING. PROVIDER AND MOTHER WERE NEAR PT, I GOT A GLASS OF WATER, ORANGE JUICE AND A WET TOWEL. RETURNED TO PT AND PROVIDER WAS FANNING HER, MOTHER NEAR. PT WAS VERY PALE, DISORIENTED AND RAMBLING HER SPEACH. PT DID NOT LOOSE CONSCIOUSNESS. PT WAS INSTRUCTED TO DRINK SOME WATER, WE KEPT HER TALKING, THE COLD WET TOWEL WAS PLACED AROUND HER NECK. PT CONTINUED TO HAVE SOME SHAKIENESS BUT WAS SLOWLY RECOVERING. PROVIDER KEPT TALKING TO HER. PT WAS GIVEN SOME ORANGE JUICE. APROXIMATELY 10 MIN PT HAD RECOVERED, SHE WAS SLIGHTY SHAKY AND WHEN SHE SPOKE SHE MADE SENSE. PT WAS NO LONGER PALE AND REMAINED SITTING FOR APROX ANOTHER 5 MIN. PT REQUESTED TO LEAVE, INSTRUCTED HER TO STAND UP . PT REPORTED FEELING MUCH BETTER AND WANTED TO LEAVE WITH HER MOTHER. PROVIDER WALKED WITH PT AND MOTHER TO HER VEHICLE, NO FURTHER CONCERNS NOTED.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Tremor
- Hospital-Tage
- -
- Labordaten
- NONE
- Aktuelle Erkrankungen
- NONE
- Vorgeschichte
- NONE
- Andere Medikamente
- NONE
- Allergien
- SHAMPOO COMBINATION NO 1 PERFUMES-NOT SPECIFIED
- Vorherige Impfungen
- -
- Staat
- CA
- Alter
- 16,0
- Geschlecht
- M
- Eingang
- 03.03.2023
- Impfdatum
- 02.03.2023
- Beginn
- 02.03.2023
- Tage bis Beginn
- 0,0
- Dosis
- 2
- Route/Site
- IM / RA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Dizziness
Hyperhidrosis
Immediate post-injection reaction
Nausea
Pallor
Rash
Urticaria
Vomiting
Symptomtext
IMMEDIATELY POST VACCINES PATIENT COMPLAINED OF LIGHT HEADINESS, NAUSEA, BECAME SWEATY, PALE, AND BEGAN VOMITING. 1ST AID TREATMENT PROVIDED. PATIENT REMAINED IN CLINIC FOR FURTHER OBSERVATION AND STABILIZATION. AT APPROX 2:20 GUARDIAN REPORTS APPEARANCE OF RASH TO BOTH ARMS. AT 2:20 PM RASH WITH HIVE LIKE APPEARANCE NOTED OVER BOTH ARMS AND CHEST/TRUNK OF PATIENT'S BODY. AT 2:21 Public Health Nurse administered 50mg/1ml of DiphenhydrAMINE administered into the right leg via IM injection. EMS ACTIVATED AT 2:23 PM PATIENT TRANSPORTED TO HOSPITAL AT 2:37PM.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Dizziness
- Hospital-Tage
- -
- Labordaten
- UNKNOWN
- Aktuelle Erkrankungen
- NONE; VERBALIZED BY GUARDIAN WITH SCEENING QUESTIONS.
- Vorgeschichte
- NONE; VERBALIZED BY GUARDIAN WITH SCEENING QUESTIONS.
- Andere Medikamente
- NONE; VERBALIZED BY GUARDIAN WITH SCEENING QUESTIONS.
- Allergien
- GUARDIAN VERBALIZED GRASS CAUSES MILD REACTION WITH DIRECT CONTANT TO SKIN
- Vorherige Impfungen
- -
- Staat
- WA
- Alter
- 15,0
- Geschlecht
- F
- Eingang
- 24.12.2022
- Impfdatum
- 08.12.2022
- Beginn
- 08.12.2022
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: ja
Erholt: ja
Dizziness
Pharyngeal swelling
Rash erythematous
Rash papular
Symptomtext
Seen in clinic on 12/8 and received hep A (right deltoid) and HPV/MenQuadFi (left deltoid), first dose for each. Developed a rash on her dorsal right wrist (about 5 cm area of pink raised spots, non-pruritic, not bothersome), throat swelling, and lightheadedness about 45 minutes after receiving the vaccines. No difficulty breathing. Went to urgent care and, per note, had a reassuring exam. Received Benadryl and was prescribed epi pen. Rash and throat gradually improved after getting Benadryl and had resolved within a few hours. Lightheadedness lasted most of the night but had mostly improved by the morning, fully resolved after about 24 hours. No prior history of allergies or vaccine reactions. Was otherwise feeling like herself prior to vaccines and once recovered. No recent fever, cough, or runny nose.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Dizziness
- Hospital-Tage
- -
- Labordaten
- None
- Aktuelle Erkrankungen
- None
- Vorgeschichte
- Depression Anxiety
- Andere Medikamente
- sertraline 50 mg daily hydroxyzine 25 mg PRN
- Allergien
- No known allergies
- Vorherige Impfungen
- -
- Staat
- ID
- Alter
- 12,0
- Geschlecht
- F
- Eingang
- 16.11.2022
- Impfdatum
- 15.11.2022
- Beginn
- 15.11.2022
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / RA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Altered state of consciousness
Disorientation
Dizziness
Fatigue
Hyperhidrosis
Nausea
Pain in extremity
Pallor
Respiratory rate decreased
Speech disorder
Unresponsive to stimuli
Vomiting
Symptomtext
On 11/15/22 patient came in to receive catch-up vaccines. She had one vaccine in the past about one year ago (Tdap). Father did ask about side effects and response if the patient received 8 vaccines. I discussed with the father that we have provided that many vaccines to patients in the past and they did well. But it It?s hard to know because everyone is different. Usual side effects are redness, some swelling at the injection site and the day after some fatigue. I stated that everyone response differently. He chose to do 4 out of the 8 vaccines but the patient wanted and insisted to do all 8 and get them over with so the father decided to do the 8 vaccines to get her caught up. I did educate the patient and father again of side effects-sore arm, and legs. Maybe redness and swelling at the injection site. If she did get a fever to give her Tylenol and or Ibuprofen as directed on the bottle. Patient was educated to drink water- stay hydrated and to move extremities for soreness. Patient and patients father voiced understanding. At approximately 3:25 9 vaccines (Hep A, Hep B, MMR, Varicella, Tdap, IPV, HPV, Menquadfi) were administered to the patient. She received the vaccines in both right/left deltoids and 2 vaccines in both thighs- right and left. A few seconds after the last vaccine administration patient became unresponsive very pale, diaphoretic, and respirations decreased. She would respond to stimuli by opening her eyes. Her face and lips turned pale and she was had slow respirations. I precede to use the ammonia inhalant and that aroused her. Pt was not oriented. She would respond to her name and open her eyes. She was asked to say her name and she was unable to say her name or birthday. She stated she felt nausea and dizzy and wanted to vomit. She was given a few sips of water from her father. He assisted in trying to arouse and talk to her. She then vomited and stated she felt better. She continued to be pale and go in and out of consciousness so I used the ammonia inhalant and that aroused her. At approximately 3:41pm called EMS and I drew up 0.45msl of epinephrine to have on hand. At approximately 3:50 EMS and fire department showed up. I gave them report of the situation and helped move the exam table out to lie the patient down they asked the patients father questions about allergies, last meal. They took vital signs and monitored the patient. After about 35 minutes of the paramedics/ fire department monitoring the patient, she stated she felt better and she sat up. She was able to stand up and walk on her own around the room. At that time the patients father reported he felt comfortable taking the patient home. They set up the next visit in 2 months for one vaccine. I did educate both the patient and father that prior to that appointment make sure the patient has had something to eat, and to come in hydrated. They both voiced understanding. She exited the building ambulating next to her father. EMS and fire department also exited the building approximately the same time 4:25pm. 11/16/22 at approximately 10:52 a.m. I followed up via phone with the patient?s father on how the patient was feeling today. He reported that she stayed home from school because she did vomit in the morning. He reported that the patient stated she?s feeling better, she did report feeling tired and her arms and legs are sore. Re-educated patients? father on the important of movement in the extremities and keeping hydrated as much as possible. He voiced understanding. I did let him know I made a VAERS report and explained that to help. He voiced understanding. VAERS report done on 11/16/22.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Dizziness
- Hospital-Tage
- -
- Labordaten
- n/a
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- none
- Andere Medikamente
- none
- Allergien
- none
- Vorherige Impfungen
- -
- Staat
- IL
- Alter
- 11,0
- Geschlecht
- M
- Eingang
- 08.11.2022
- Impfdatum
- 08.11.2022
- Beginn
- 08.11.2022
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Fatigue
Malaise
Symptomtext
The patient was present at the school base center for his 11-year-old well exam. MCV4 and TDaP given. Patient did not feel well. Positioned patient supine with HOB slightly elevated and legs up. Patient able to respond verbally. Patient feeling well and states normal within few minutes. Able to drink water and snack. Patient and mother reviewed risks and occurrence. Consented to continue vaccines. Positioned in supine, HOB up, talking throughout vaccines, HPV and Flu given. Felt tired. Legs up again. Symptoms resolved after few minutes. Maintained position HOB slightly elevated and supine for 15 minutes. No orthostatic hypotension with BP checks positionally. Pulse and pulse ox remained stable.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Fatigue
- Hospital-Tage
- -
- Labordaten
- BP, pulse, pulse ox normal
- Aktuelle Erkrankungen
- None - Mother reported the child was not sick and feeling well prior to receiving the vaccines.
- Vorgeschichte
- Learning disability
- Andere Medikamente
- None
- Allergien
- Fish containing products
- Vorherige Impfungen
- -
- Staat
- NY
- Alter
- 12,0
- Geschlecht
- F
- Eingang
- 28.10.2022
- Impfdatum
- 16.09.2022
- Beginn
- 19.09.2022
- Tage bis Beginn
- 3,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Injection site urticaria
Symptomtext
hives, recurrent over several weeks, starting at site of injection
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Injection site urticaria
- Hospital-Tage
- -
- Labordaten
- none
- Aktuelle Erkrankungen
- none
- Vorgeschichte
- glaucoma/cataract
- Andere Medikamente
- latanaprost eye drops
- Allergien
- none
- Vorherige Impfungen
- -
- Staat
- AZ
- Alter
- 17,0
- Geschlecht
- M
- Eingang
- 26.10.2022
- Impfdatum
- 25.10.2022
- Beginn
- 25.10.2022
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / RA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Immediate post-injection reaction
Rash
Symptomtext
Pt broke out In rash immediately after vaccination administered, he was given 25mg Benadryl on site. Pt was transferred out to Hospital to receive care.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Rash
- Hospital-Tage
- -
- Labordaten
- N/A
- Aktuelle Erkrankungen
- N/A
- Vorgeschichte
- N/A
- Andere Medikamente
- N/A
- Allergien
- Allergies to mayonaise
- Vorherige Impfungen
- -
- Staat
- -
- Alter
- 17,0
- Geschlecht
- M
- Eingang
- 26.09.2022
- Impfdatum
- 26.09.2022
- Beginn
- 26.09.2022
- Tage bis Beginn
- 0,0
- Dosis
- 2
- Route/Site
- IM / RA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Dizziness
Hyperhidrosis
Symptomtext
patient became light headed and sweaty after getting vaccines patient laid down. patient felt better. blood pressure was taken 106/62 patient stayed for 10 more min. and blood pressure was taken again 132/67 patient was allowed to leave.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Dizziness
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- multivitamin
- Allergien
- nka
- Vorherige Impfungen
- -
- Staat
- CA
- Alter
- 15,0
- Geschlecht
- F
- Eingang
- 07.09.2022
- Impfdatum
- 07.09.2022
- Beginn
- 07.09.2022
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / RA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Hyperhidrosis
Nausea
Pallor
Symptomtext
A 15 yrs 11 month old female student looked pale, sweating, felt nauseous after receiving the four vaccines. She is assisted to lay down on the floor with her feet elevated. O2 5 liters given. Vital signs taken: 2:35pm: BP 122/85, HR 84, RR 16,O2 sat 100% 2:37pm: BP 121/91, HR 93, RR 16, O2 sat 99%, Color pink, no nausea or dizziness, no shortness of breath 2:40pm: BP 121/84, HR 84, RR 20, O2 sat 99% 2:42pm:BP (sitting) 101/66, HR 87, RR 20, O2 sat 100%, denied dizziness 2:45pm:BP (sitting) 118/66, HR 64, RR 20, O2 sat 100% on room air. 2:50pm: BP(Sitting) 103/67, HR 68, RR 20, O2 sat 98% 2:55pm BP(Sitting) 107/64, HR 69, RR 16, O2 sat 99% 3:00pmBP(Standing) 97/61, HR 81, RR 16 O2 sat 100%, denied dizziness 3:05pm BP (Standing) 113/69, HR 69, RR 16, O2 sat 100% She is awake and responds to verbal stimuli the whole time. Student went home with her mother and guardian. Refer to seek medical care for difficulty breathing and chest tightness. Mother and guardian understand the instructions.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Nausea
- Hospital-Tage
- -
- Labordaten
- None
- Aktuelle Erkrankungen
- None
- Vorgeschichte
- None
- Andere Medikamente
- None
- Allergien
- None
- Vorherige Impfungen
- -
- Staat
- -
- Alter
- -
- Geschlecht
- U
- Eingang
- 06.10.2023
- Impfdatum
- 28.09.2023
- Beginn
- 28.09.2023
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- OT / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Expired product administered
No adverse event
Symptomtext
expired Menquadfi Vaccine administered with no reported adverse event; Initial information received on 29-Sep-2023 regarding an unsolicited valid non-serious case received from a other health professional. This case involves patient with unknown demographics who received expired meningococcal A-C-Y-W135 (T CONJ) vaccine [Menquadfi] vaccine administered with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 28-Sep-2023, the patient received a dose of suspect Meningococcal A-C-Y-W135 (T CONJ) Vaccine Solution for injection expiry date: 24-sep-2023 Lot u7449ab via unknown route in unknown administration site for prophylactic vaccination (immunization). On 28-SEP-2023 the patient received expired menquadfi vaccine administered with no reported adverse event (expired product administered) on the same day. Action taken was not applicable. At time of reporting, the outcome was Unknown for the event expired menquadfi vaccine administered with no reported adverse event. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Expired product administered
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- OH
- Alter
- 12,0
- Geschlecht
- M
- Eingang
- 22.08.2023
- Impfdatum
- 13.08.2023
- Beginn
- 13.08.2023
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Extra dose administered
No adverse event
Symptomtext
Pt received duplicate vaccination according to staff at primary care office. provider's office states that the pt received these last year. Pt denies any adverse effects. Office notes that they do not report to system, the vaccine database, so administering pharmacist provided based on (signing guardian)'s statement that the immunizations were needed.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Extra dose administered
- Hospital-Tage
- -
- Labordaten
- none
- Aktuelle Erkrankungen
- no known illnesses
- Vorgeschichte
- none
- Andere Medikamente
- no known medications
- Allergien
- no known allergies
- Vorherige Impfungen
- -
- Staat
- NV
- Alter
- 13,0
- Geschlecht
- F
- Eingang
- 12.07.2023
- Impfdatum
- 12.07.2023
- Beginn
- -
- Tage bis Beginn
- -
- Dosis
- 2
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Extra dose administered
Symptomtext
GIVEN EXTRA DOSE OF MEN ACWY. REPORTED TO VAERS. CONTACTED PATIENT TO COME IN FOR SECOND MEN B ON JULY 13, 2023.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Extra dose administered
- Hospital-Tage
- -
- Labordaten
- N/A
- Aktuelle Erkrankungen
- NONE
- Vorgeschichte
- NONE
- Andere Medikamente
- -
- Allergien
- NKA
- Vorherige Impfungen
- -
- Staat
- WA
- Alter
- 15,0
- Geschlecht
- F
- Eingang
- 20.06.2023
- Impfdatum
- 14.11.2022
- Beginn
- 14.11.2022
- Tage bis Beginn
- 0,0
- Dosis
- 2
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Unevaluable event
Symptomtext
Vaccines administered by RN.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Unevaluable event
- Hospital-Tage
- -
- Labordaten
- none
- Aktuelle Erkrankungen
- none known
- Vorgeschichte
- constipation/anxiety/depression
- Andere Medikamente
- Albuterol PRN Cetirizine PRN Vitamin D Fluoxetine Hydroxyzine PRN Zaditor eye gtts Miralax PRN Sennosides PRN
- Allergien
- NKDA
- Vorherige Impfungen
- -
- Staat
- WA
- Alter
- 18,0
- Geschlecht
- M
- Eingang
- 18.03.2023
- Impfdatum
- 16.12.2022
- Beginn
- 16.12.2022
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- OT / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
No adverse event
Poor quality product administered
Product storage error
Symptomtext
MENQUADFI was in a previous excursion and was administered after the excursion with no reported adverse event; MENQUADFI was in a previous excursion and was administered after the excursion with no reported adverse event; Initial information received on 10-Mar-2023 regarding an unsolicited valid non-serious case received from a healthcare professional. This case is linked to case 2023SA082363(CLUSTER). This case involves an 18-year-old male patient, to whom MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE [MENQUADFI] was in a previous excursion and was administered after the excursion with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 16-Dec-2022, the patient received 0.5ml total dose of suspect MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE Solution for injection (strength: standard) (lot number: U7449AB, expiry date: 23-Sep-2024) via intramuscular route in unknown administration site for Immunization on the same day menquadfi was in a previous excursion and was administered after the excursion with no reported adverse event (poor quality product administered), (product storage error). It was reported, caller originally stated that it was not administered post excursion. Caller is requesting revaccination information. No additional information available. This situation is reported as a medication error due to administration of MENQUADFI post excursion. Action taken with MENINGOCOCCAL VACCINE (MENQUADFI) was not applicable. At time of reporting, the outcome was Unknown for both events. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- No adverse event
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- WA
- Alter
- 14,0
- Geschlecht
- F
- Eingang
- 18.03.2023
- Impfdatum
- 16.12.2022
- Beginn
- 16.12.2022
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- OT / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
No adverse event
Poor quality product administered
Product storage error
Symptomtext
Menquadfi administered after the excursion with no reported event; Initial information received on 10-Mar-2023 regarding an unsolicited valid non-serious case received from other health professional. This case is linked to cases 2023SA082363 and 2023SA082367. This case involves a 14-year-old female patient to whom meningococcal A-C-Y-W135 (T CONJ) Vaccine [Menquadfi] administered after the excursion with no reported event. The patient's past medical history, medical treatment(s), vaccination(s), concomitant medication and family history were not provided. On 16-Dec-2022, the patient received suspect meningococcal A-C-Y-W135 (T CONJ) Vaccine solution for injection at a dose of 0.5 ml total (lot U7449AB, expiry date: 23-Sep-2024) via intramuscular route in unknown administration site for immunization. On 16-Dec-2022, menquadfi administered after the excursion with no reported event (poor quality product administered, latency: same day). Action taken: Not applicable. Outcome: Unknown. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.; Sender's Comments: US-SA-2023SA082418:
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- No adverse event
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- WA
- Alter
- 17,0
- Geschlecht
- F
- Eingang
- 18.03.2023
- Impfdatum
- 20.12.2022
- Beginn
- 20.12.2022
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- OT / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
No adverse event
Product storage error
Symptomtext
Menquadfi was administered after the excursion, with no reported adverse event; Initial information received on 10-Mar-2023 regarding an unsolicited valid non-serious case received via health professional. Number: 01527753. This case involves 17 years old female patient to whom MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE [MENQUADFI] was administered after the excursion, with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. This case is linked to cases 2023SA082418, 2023SA082416, 2023SA081681, 2023SA082363, 2023SA082367, 2023SA082373, 2023SA082953 and 2023SA082675. On 20-Dec-2022, the patient received suspect MENINGOCOCCAL A-C-Y-W135 (T CONJ) vaccine Solution for injection at dose 0.5ml once (lot: U7449AB, expiry date: 23-Sep-2029) via intramuscular route in unknown administration site for immunization after the excursion, with no reported adverse event (poor quality product administered) at same day latency. Action taken with MENINGOCOCCAL VACCINE (MENQUADFI) was not applicable. No corrective treatment was received for the event. At time of reporting, the outcome was Unknown for the event poor quality product administered. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- No adverse event
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- WA
- Alter
- 11,0
- Geschlecht
- M
- Eingang
- 18.03.2023
- Impfdatum
- 10.01.2023
- Beginn
- 10.01.2023
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- OT / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
No adverse event
Product storage error
Symptomtext
menquadfi administered post excursion with no reported adverse events; Initial information received on 10-Mar-2023 regarding an unsolicited valid non-serious case received from a other health professional. This case is linked to case 2023SA082418. This case involves a 11 years old male patient and reporter reported Meningococcal A-C-Y-W135 (T Conj) Vaccine [Menquadfi] was administered post excursion with no reported adverse events. The patient's past medical history, medical treatment(s), concomitant medication(s), vaccination(s) and family history were not provided. On 10-Jan-2023, the patient received 0.5 mL dose of suspect meningococcal A-C-Y-W135 (T CONJ) vaccine, Solution for injection (frequency- once (1x), lot U7449AB, expiry date - 23-Sep-2024, strength - unknown) via intramuscular route in unknown administration site for immunization post excursion with no reported adverse event (poor quality product administered) (Latency: same day). Action taken: not applicable. Outcome: Unknown for the reported event This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- No adverse event
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- WA
- Alter
- 16,0
- Geschlecht
- F
- Eingang
- 18.03.2023
- Impfdatum
- 11.01.2023
- Beginn
- 11.01.2023
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- OT / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Poor quality product administered
Product storage error
Symptomtext
administration of menquadfi post excursion with no adverse event; Initial information received on 10-Mar-2023 regarding an unsolicited valid non-serious case received from other health professional. This case is linked to cases 2023SA082416, 2023SA082675 and 2023SA082363. This case involves a 16-year-old female patient who had administration of meningococcal A-C-Y-W135 (T CONJ) vaccine [Menquadfi]post excursion with no adverse event. The patient's past medical history, medical treatment(s), vaccination(s), concomitant medication and family history were not provided. On 11-Jan-2023, the patient received suspect meningococcal A-C-Y-W135 (T CONJ) vaccine solution for injection at a dose of 0.5 ml total (lot U7449AB, expiry date: 23-Sep-2024) via intramuscular route in unknown administration site for immunization. On 11-Jan-2023 the patient had administration of menquadfi post excursion with no adverse event (poor quality product administered, same day latency). Action taken: Not applicable. Outcome: Unknown. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Poor quality product administered
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- WA
- Alter
- 11,0
- Geschlecht
- M
- Eingang
- 18.03.2023
- Impfdatum
- 11.01.2023
- Beginn
- 11.01.2023
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- OT / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Poor quality product administered
Symptomtext
administration of Menquadfi post excursion without adverse event; Initial information received on 10-Mar-2023 regarding an unsolicited valid non-serious case received via health professional. Number: 01527689. This case involves 11 years old male patient to whom Meningococcal A-C-Y-W135 (T CONJ) Vaccine [Menquadfi] post excursion without adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. This case is linked to cases 2023SA082367, 2023SA082373, 2023SA082418, 2023SA082416, 2023SA082675, 2023SA082382, 2023SA082953 and 2023SA081681. On 11-Jan-2023, the patient received suspect MENINGOCOCCAL A-C-Y-W135 (T CONJ) vaccine Solution for injection at dose 0.5ml once (lot: U7449AB, expiry date: 23-Sep-2024) via intramuscular route in unknown administration site for immunization after the excursion, with no reported adverse event (poor quality product administered) at same day latency. Action taken with MENINGOCOCCAL VACCINE (MENQUADFI) was not applicable. No corrective treatment was received for the event. At time of reporting, the outcome was Unknown for the event poor quality product administered. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Poor quality product administered
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- WA
- Alter
- 16,0
- Geschlecht
- M
- Eingang
- 18.03.2023
- Impfdatum
- 16.12.2022
- Beginn
- 16.12.2022
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- OT / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
No adverse event
Product storage error
Symptomtext
Administration of MENQUADFI post excursion with no reported adverse event; Initial information received on 10-Mar-2023 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 16 years old male patient who was administrated with vaccine Meningococcal a-c-y-w135 (t conj) vaccine [MENQUADFI].post excursion with no reported adverse event The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 16-Dec-2022, the patient received suspect Meningococcal a-c-y-w135 (t conj) vaccine Solution for injection at dose of 0.5 ml total (strength were not reported) (lot U7449AB and expiry date-23-sep-2024) via intramuscular route in unknown administration site for immunization after post excursion with no reported adverse event (poor quality product administered) (latency-same day). Action taken was not applicable. At time of reporting, the outcome was Unknown for the event. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.; Sender's Comments: US-SA-2023SA082418:
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- No adverse event
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- WA
- Alter
- 15,0
- Geschlecht
- M
- Eingang
- 18.03.2023
- Impfdatum
- 10.01.2023
- Beginn
- 10.01.2023
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- OT / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
No adverse event
Poor quality product administered
Product storage error
Symptomtext
administration of menquadfi post excursion with no reported adverse event; Initial information received on 10-Mar-2023 regarding an unsolicited valid non-serious case received from a other health professional. This case is linked to cases 2023SA082363(CLUSTER) and 2023SA082367(CLUSTER). This case involves a 15 years old male patient and it was reported administration of meningococcal A-C-Y-W135 (T CONJ) vaccine [Menquadfi] post excursion with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s), concomitants and family history were not provided. On 10-Jan-2023, it was reported administration of 0.5 mL of meningococcal A-C-Y-W135 (T CONJ) vaccine [Menquadfi] solution for injection (batch/lot number: U7449AB and expiry date: 23-SEP-2024; strength, route: unknown) in unknown administration site for Immunization post excursion with no reported adverse event (poor quality product administered) (latency: same day). Action taken: Not applicable. At time of reporting, the outcome was Unknown for the event. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.; Sender's Comments: US-SA-2023SA082418:
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- No adverse event
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- WA
- Alter
- 13,0
- Geschlecht
- F
- Eingang
- 17.03.2023
- Impfdatum
- 13.12.2022
- Beginn
- 13.12.2022
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- OT / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
No adverse event
Poor quality product administered
Product storage error
Symptomtext
Administration of Menquadfi post excursion with no reported adverse event; Initial information received on 10-Mar-2023 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 13 years old female patient who was administered meningococcal A-C-Y-W135 (T CONJ) vaccine [Menquadfi] post excursion with no reported adverse event. The patient's past medical history, medical treatment(s), concomitant medication(s), vaccination(s) and family history were not provided. On 13-Dec-2022, the patient received 0.5 mL dose of suspect meningococcal A-C-Y-W135 (T CONJ) vaccine, Solution for injection (frequency- once (1x), lot U7449AB, expiry date - 23-Sep-2024, strength - unknown) via intramuscular route in unknown administration site for immunization post excursion with no reported adverse event (poor quality product administered) (Latency: same day). Action taken: not applicable. At time of reporting, the outcome was Unknown for the event. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.; Sender's Comments: US-SA-2023SA082363:linked report US-SA-2023SA082367:linked report US-SA-2023SA081681:linked report US-SA-2023SA082373:linked report US-SA-2023SA082416:linked report US-SA-2023SA082953:linked report US-SA-2023SA082382:linked report US-SA-2023SA082675:linked report US-SA-2023SA082418:linked report US-SA-2023SA082418:linked report
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- No adverse event
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- CA
- Alter
- 13,0
- Geschlecht
- F
- Eingang
- 16.03.2023
- Impfdatum
- 13.01.2023
- Beginn
- 13.01.2023
- Tage bis Beginn
- 0,0
- Dosis
- 2
- Route/Site
- IM / UN
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Inappropriate schedule of product administration
No adverse event
Symptomtext
Patient received the second dose of Meningococcal vaccine too early, she should have received it when she was 16 years old. She did not have any adverse reactions to the vaccine. Clinic called patients father and informed him of the error, patient and father acknowledged and expressed understanding.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Inappropriate schedule of product administration
- Hospital-Tage
- -
- Labordaten
- none
- Aktuelle Erkrankungen
- none
- Vorgeschichte
- epigastric pain, generalized anxiety
- Andere Medikamente
- pediatric multivitamin-iron (poli-vi-sol with iron), polyethylene glycol, PEG 3350 mg 17 g/dose, clotrimazole 1%.
- Allergien
- NKDA.
- Vorherige Impfungen
- -
- Staat
- NE
- Alter
- 11,0
- Geschlecht
- F
- Eingang
- 14.02.2023
- Impfdatum
- 14.02.2023
- Beginn
- 14.02.2023
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Extra dose administered
Symptomtext
Patient seen for well child check and vaccines. After receiving vaccines including COVID Bivalent vaccine, mother called office informing triage nurse that patient did receive COVID Bivalent vaccine 11/9/2022 at pharmacy. This was not in our charting system. Patients primary physician notified of this.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Extra dose administered
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- OR
- Alter
- 9,0
- Geschlecht
- F
- Eingang
- 08.02.2023
- Impfdatum
- 08.02.2023
- Beginn
- 08.02.2023
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Product administered to patient of inappropriate age
Symptomtext
Pt given MCV4 prior to being old enough
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Product administered to patient of inappropriate age
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- unknown
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- ND
- Alter
- 11,0
- Geschlecht
- M
- Eingang
- 01.02.2023
- Impfdatum
- 26.01.2023
- Beginn
- 26.01.2023
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Expired product administered
Symptomtext
Patient was given Pfizer Bivalent 5-11 COVID vaccine that had a BUD of 01/25/2023. Vaccine was administered 1 day after BUD. Spoke to Pfizer, they stated there is an additional two-day stability period beyond the 10-week BUD. This is considered a valid administration and the patient is not at risk for any harm due to this.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Expired product administered
- Hospital-Tage
- -
- Labordaten
- None
- Aktuelle Erkrankungen
- None
- Vorgeschichte
- None
- Andere Medikamente
- None
- Allergien
- None known
- Vorherige Impfungen
- -
- Staat
- AZ
- Alter
- 11,0
- Geschlecht
- M
- Eingang
- 26.01.2023
- Impfdatum
- 23.01.2023
- Beginn
- 23.01.2023
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Local reaction
Symptomtext
developed a local reaction to HPV site , no fever, shortness of breath no skin lesions. Started on topical steroid, use cool compress as needed and continue supportive measures. He is to follow up in 2-3 days.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Local reaction
- Hospital-Tage
- -
- Labordaten
- none
- Aktuelle Erkrankungen
- none
- Vorgeschichte
- none
- Andere Medikamente
- none
- Allergien
- none
- Vorherige Impfungen
- -
- Staat
- WA
- Alter
- 11,0
- Geschlecht
- M
- Eingang
- 19.01.2023
- Impfdatum
- 16.01.2023
- Beginn
- 16.01.2023
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- - / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Incorrect dose administered
Symptomtext
Pfizer 12+ COVID BIVBoost given to 11 year old patient.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Incorrect dose administered
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- N/A
- Vorgeschichte
- N/A
- Andere Medikamente
- N/A
- Allergien
- N/A
- Vorherige Impfungen
- -
- Staat
- ID
- Alter
- 6,0
- Geschlecht
- M
- Eingang
- 16.12.2022
- Impfdatum
- 16.12.2022
- Beginn
- 16.12.2022
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / RL
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Wrong patient received product
Symptomtext
Immunizations were given to the incorrect patient.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Wrong patient received product
- Hospital-Tage
- -
- Labordaten
- none
- Aktuelle Erkrankungen
- none
- Vorgeschichte
- Asthma
- Andere Medikamente
- Flovent and Albuterol
- Allergien
- none
- Vorherige Impfungen
- -
- Staat
- AZ
- Alter
- -
- Geschlecht
- U
- Eingang
- 02.11.2022
- Impfdatum
- 05.10.2022
- Beginn
- 05.10.2022
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- OT / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Medication error
No adverse event
Poor quality product administered
Product storage error
Symptomtext
temperature excursion of unknown cause, Max/low temperature reached: 32.7F Duration out of labelled range: 1 hour with no reported adverse event; 2 patients were administered menquadfi post excursion with no reported adverse event; Initial information received on 25-Oct-2022 regarding an unsolicited valid non-serious case received from a consumer/non-hcp. This case involves 2 patients who received vaccine MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE [MENQUADFI] and had temperature excursion of unknown cause, max/low temperature reached: 32.7f duration out of labelled range: 1 hour with no reported adverse event and 2 patients were administered menquadfi post excursion with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date there was temperature excursion of unknown cause, max/low temperature reached: 32.7f duration out of labelled range: 1 hour with no reported adverse event (product storage error). On 05-Oct-2022, the patient received an unknown dose of suspect MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE (formulation, strength: unknown) lot U7449AB, expiration date: 23-Sep-2024 via unknown route in unknown administration site as Immunization. On 05-OCT-2022 the 2 patients were administered menquadfi post excursion with no reported adverse event (poor quality product administered) same day following the administration of MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE.A mini refrigerator was used and it experienced a low excursion. Action taken was not applicable. It was not reported if the patient received a corrective treatment for the events (temperature excursion of unknown cause, Max/low temperature reached: 32.7F Duration out of labelled range: 1 hour with no reported adverse event, 2 patients were administered menquadfi post excursion with no reported adverse event). At time of reporting, the outcome was Unknown for all. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Medication error
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- OR
- Alter
- 11,0
- Geschlecht
- M
- Eingang
- 21.10.2022
- Impfdatum
- 20.10.2022
- Beginn
- 21.10.2022
- Tage bis Beginn
- 1,0
- Dosis
- 1
- Route/Site
- IM / LL
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
No adverse event
Product administered to patient of inappropriate age
Symptomtext
Patient was given Flublock which is approved for 18+ allergic to eggs, instead of flu vaccine for 6 months+. No adverse effects at this time
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- No adverse event
- Hospital-Tage
- -
- Labordaten
- n/a
- Aktuelle Erkrankungen
- n/a
- Vorgeschichte
- ADHD, Anxiety
- Andere Medikamente
- amphetamine-dextroamphetamine 15mg amphetamine-dextroamphetamine 10mg guanfacine 1mg melatonin 10mg
- Allergien
- penicillin
- Vorherige Impfungen
- -
- Staat
- AZ
- Alter
- 15,0
- Geschlecht
- M
- Eingang
- 21.10.2022
- Impfdatum
- 21.10.2022
- Beginn
- 21.10.2022
- Tage bis Beginn
- 0,0
- Dosis
- 2
- Route/Site
- IM / RA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Extra dose administered
Symptomtext
Patient got an extra dose of tdap and MCV 4 outside of recommended schedule.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Extra dose administered
- Hospital-Tage
- -
- Labordaten
- NONE
- Aktuelle Erkrankungen
- n/a
- Vorgeschichte
- n/a
- Andere Medikamente
- n/a
- Allergien
- n/a
- Vorherige Impfungen
- -
- Staat
- AZ
- Alter
- -
- Geschlecht
- M
- Eingang
- 21.10.2022
- Impfdatum
- 21.10.2022
- Beginn
- 21.10.2022
- Tage bis Beginn
- 0,0
- Dosis
- 2
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Extra dose administered
Symptomtext
Patient got an extra dose of tdap outside of recommended schedule.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Extra dose administered
- Hospital-Tage
- -
- Labordaten
- none
- Aktuelle Erkrankungen
- n/a
- Vorgeschichte
- n/a
- Andere Medikamente
- n/a
- Allergien
- n/a
- Vorherige Impfungen
- -